A Human Liver‐on‐a‐Chip Platform for Modeling Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The liver possesses a unique microenvironment with a complex internal vascular system and cell–cell interactions. Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease, and although much effort has been dedicated to building models to target NAFLD, most in vitro systems rely on simple models failing to recapitulate complex liver functions. Here, an in vitro system is presented to study NAFLD (steatosis) by coculturing human hepatocellular carcinoma (HepG2) cells and umbilical vein endothelial cells (HUVECs) into spheroids. Analysis of colocalization of HepG2–HUVECs along with the level of steatosis reveals that the NAFLD pathogenesis could be better modeled when 20% of HUVECs are presented in HepG2 spheroids. Spheroids with fat supplements progressed to the steatosis stage on day 2, which could be maintained for more than a week without being harmful for cells. Transferring spheroids onto a chip system with an array of interconnected hexagonal microwells proves helpful for monitoring functionality through increased albumin secretions with HepG2–HUVEC interactions and elevated production of reactive oxygen species for steatotic spheroids. The reversibility of steatosis is demonstrated by simply stopping fat‐based diet or by antisteatotic drug administration, the latter showing a faster return of intracellular lipid levels to the basal level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Cell-laden microengineered gelatin methacrylate hydrogels
Nichol, J. W., Koshy, S. T., Bae, H., Hwang, C. M., Yamanlar, S., & Khademhosseini, A. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.03.064 · Cited by 2,377
Self-citationOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
A liver-on-a-chip platform with bioprinted hepatic spheroids
Bhise, N. S., Manoharan, V., Massa, S., Tamayol, A., Ghaderi, M., Miscuglio, M., Lang, Q., Shrike Zhang, Y., Shin, S. R., Calzone, G., et al. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/014101 · Cited by 615
Self-citationAnimal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2300 · Cited by 554
Metabolic zonation of the liver: The oxygen gradient revisited
Kietzmann, T. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.012 · Cited by 499
Liver zonation: Novel aspects of its regulation and its impact on homeostasis
Gebhardt, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8491 · Cited by 275
Moshksayan, K., Kashaninejad, N., Warkiani, M. E., Lock, J. G., Moghadas, H., Firoozabadi, B., Saidi, M. S., & Nguyen, N.-T. (2018) · Sensors and Actuators B: Chemical · doi:10.1016/j.snb.2018.01.223 · Cited by 267
Wiśniewski, J. R., Vildhede, A., Norén, A., & Artursson, P. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.01.016 · Cited by 185
Cited by
Teng, Y., Zhao, Z., Tasnim, F., Huang, X., & Yu, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120904 · Cited by 62
Suurmond, C. E., Lasli, S., van den Dolder, F. W., Ung, A., Kim, H., Bandaru, P., Lee, K., Cho, H., Ahadian, S., Ashammakhi, N., et al. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201901379 · Cited by 61
Self-citationConstructing biomimetic liver models through biomaterials and vasculature engineering
Lv, W., Zhou, H., Aazmi, A., Yu, M., Xu, X., Yang, H., Huang, Y. Y. S., & Ma, L. (2022) · Regenerative Biomaterials · doi:10.1093/rb/rbac079 · Cited by 45
Critical Considerations for the Design of Multi-Organ Microphysiological Systems (MPS)
Malik, M., Yang, Y., Fathi, P., Mahler, G. J., & Esch, M. B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.721338 · Cited by 43
Microfluidic systems for modeling digestive cancer: a review of recent progress
Razavi, Z., Soltani, M., Pazoki-Toroudi, H., & Dabagh, M. (2024) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ad6f15 · Cited by 24
Metadata
- Authors
- Lasli, S., Kim, H., Lee, K., Suurmond, C. E., Goudie, M., Bandaru, P., Sun, W., Zhang, S., Zhang, N., Ahadian, S., Dokmeci, M. R., Lee, J., & Khademhosseini, A.
- Venue
- Advanced Biosystems
- Publisher
- Wiley
- Published
- 2019-06-14
- Volume
- 3
- Issue
- 8
- Pages
- e1900104-e1900104
- ISSN
- 2366-7478 (ISSN-L)
- OpenAlex
- W2952370024
- Cited by
- 84
- References
- 12
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Human Liver‐on‐a‐Chip Platform for Modeling Nonalcoholic Fatty Liver Disease. https://app.cochat.ai/papers/10.1002/adbi.201900104
- The paper
- Lasli, S., Kim, H., Lee, K., Suurmond, C. E., Goudie, M., Bandaru, P., Sun, W., Zhang, S., Zhang, N., Ahadian, S., Dokmeci, M. R., Lee, J., & Khademhosseini, A. (2019). A Human Liver‐on‐a‐Chip Platform for Modeling Nonalcoholic Fatty Liver Disease. Advanced Biosystems. https://doi.org/10.1002/adbi.201900104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.